Rejuvenation Technologies Inc.
mRNA therapeutics to extend healthspan entering clinical trials
Acerca de
Descripción de la empresa en inglés
Stanford-patented essential drug platform unlocks the healthspan, which is limited by short telomeres. Extends mouse lifespan by equivalent of 10 years in humans. Reverses 5-10 years of telomere shortening with one dose in one day. Preclinical efficacy in 4 organ systems including immune system. Entering clinical stage. CEO is Subject #1 in longevity trial. 50+ granted patents, 7 patent families. FDA INTERACT cleared. Raising $10M seed extension ($2M+ wired) to fund 3 investigator-initiated trials. Readouts in Q3 2027. $6.8B in comparable mRNA-LNP M&A in last 12 months.
Temas
- Ubicación
- San Francisco, CA, Estados Unidos
- Equipo
- 2 empleados
- Promoción de YC
- Summer 2018
- Estado
- Activa
- Etapa
- Etapa temprana
